EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023

Nathaniel M Lewis iD, Yuwei Zhu, Ithan D Peltan, Manjusha Gaglani iD, Tresa McNeal, Shekhar Ghamande iD, Jay S Steingrub, Nathan I Shapiro, Abhijit Duggal, William S Bender, Leyla Taghizadeh, Samuel M Brown und 39 weitere

Clinical Infectious Diseases · 10.04.2024 · 78 (4) · 1056-1064

DOI: 10.1093/cid/ciad677 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.12.2023. Verfasst von Nathaniel M Lewis und 50 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Influenza A Virus, H1N1 Subtype, Influenza A virus. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, US Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza circulation during the 2022–2023 season in the United States largely returned to pre–coronavirus disease 2019 (COVID-19)-pandemic patterns and levels. Influenza A(H3N2) viruses were detected most frequently this season, predominately clade 3C.2a1b.2a, a close antigenic match to the vaccine strain.

Methods

To understand effectiveness of the 2022–2023 influenza vaccine against influenza-associated hospitalization, organ failure, and death, a multicenter sentinel surveillance network in the United States prospectively enrolled adults hospitalized with acute respiratory illness between 1 October 2022, and 28 February 2023. Using the test-negative design, vaccine effectiveness (VE) estimates against influenza-associated hospitalization, organ failures, and death were measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2–negative control-patients.

Results

A total of 3707 patients, including 714 influenza cases (33% vaccinated) and 2993 influenza- and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–negative controls (49% vaccinated) were analyzed. VE against influenza-associated hospitalization was 37% (95% confidence interval [CI]: 27%–46%) and varied by age (18–64 years: 47% [30%–60%]; ≥65 years: 28% [10%–43%]), and virus (A[H3N2]: 29% [6%–46%], A[H1N1]: 47% [23%–64%]). VE against more severe influenza-associated outcomes included: 41% (29%–50%) against influenza with hypoxemia treated with supplemental oxygen; 65% (56%–72%) against influenza with respiratory, cardiovascular, or renal failure treated with organ support; and 66% (40%–81%) against influenza with respiratory failure treated with invasive mechanical ventilation.

Conclusions

During an early 2022–2023 influenza season with a well-matched influenza vaccine, vaccination was associated with reduced risk of influenza-associated hospitalization and organ failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza VaccinesInfluenza A Virus, H1N1 SubtypeInfluenza A virusAdultHumansUnited StatesAdolescentYoung AdultMiddle AgedInfluenza A Virus, H3N2 SubtypeVaccine EfficacyInfluenza B virusHospitalizationVaccinationSeasons

Stichwörter der Autor:innen

acute respiratory illnessattenuationinfluenzaorgan failurevaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Medicine, Intermountain Medical Center, Murray, Utah, and University of Utah, Salt Lake City, Utah, USA.
  • Baylor Scott and White Health, Temple and Dallas, Texas, and Texas A&M University College of Medicine, Temple, Texas, USA.
  • Baylor Scott and White Health, and Baylor College of Medicine, Temple, Texas, USA.
  • Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas, USA.

ORCID-Profile: Nathaniel M Lewis, Manjusha Gaglani, Shekhar Ghamande, Robert L Gottlieb, Mayur Ramesh, Basmah Safdar

Förderung

  • NIGMS NIH HHS
  • US Centers for Disease Control and Prevention
  • National Center for Immunization and Respiratory Diseases
  • NIH

Zitieren

APA

Lewis, N. M., Zhu, Y., Peltan, I. D., Gaglani, M., McNeal, T., Ghamande, S., Steingrub, J. S., Shapiro, N. I., Duggal, A., Bender, W. S., Taghizadeh, L., Brown, S. M., Hager, D. N., Gong, M. N., Mohamed, A., Exline, M. C., Khan, A., Wilson, J. G., Qadir, N., …, & Investigating Respiratory Viruses in the Acutely Ill (IVY) Network (2024). Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023. Clinical Infectious Diseases, 78(4), 1056-1064. https://doi.org/10.1093/cid/ciad677

Vancouver

Lewis NM, Zhu Y, Peltan ID, Gaglani M, McNeal T, Ghamande S, et al. Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023. Clinical Infectious Diseases. 2024;78(4):1056-1064. doi:10.1093/cid/ciad677

BibTeX
@article{Lewis2024,
  author = {Lewis, Nathaniel M and Zhu, Yuwei and Peltan, Ithan D and Gaglani, Manjusha and McNeal, Tresa and Ghamande, Shekhar and Steingrub, Jay S and Shapiro, Nathan I and Duggal, Abhijit and Bender, William S and Taghizadeh, Leyla and Brown, Samuel M and Hager, David N and Gong, Michelle N and Mohamed, Amira and Exline, Matthew C and Khan, Akram and Wilson, Jennifer G and Qadir, Nida and Chang, Steven Y and Ginde, Adit A and Mohr, Nicholas M and Mallow, Christopher and Lauring, Adam S and Johnson, Nicholas J and Gibbs, Kevin W and Kwon, Jennie H and Columbus, Cristie and Gottlieb, Robert L and Raver, Catherine and Vaughn, Ivana A and Ramesh, Mayur and Johnson, Cassandra and Lamerato, Lois and Safdar, Basmah and Casey, Jonathan D and Rice, Todd W and Halasa, Natasha and Chappell, James D and Grijalva, Carlos G and Talbot, H Keipp and Baughman, Adrienne and Womack, Kelsey N and Swan, Sydney A and Harker, Elizabeth and Price, Ashley and DeCuir, Jennifer and Surie, Diya and Ellington, Sascha and Self, Wesley H and Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network},
  title = {Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {4},
  pages = {1056--1064},
  doi = {10.1093/cid/ciad677}
}
Kostenlos starten →